DE69923439D1 - Lebendimpstoff gegen das humane immunodefizient-virus - Google Patents
Lebendimpstoff gegen das humane immunodefizient-virusInfo
- Publication number
- DE69923439D1 DE69923439D1 DE69923439T DE69923439T DE69923439D1 DE 69923439 D1 DE69923439 D1 DE 69923439D1 DE 69923439 T DE69923439 T DE 69923439T DE 69923439 T DE69923439 T DE 69923439T DE 69923439 D1 DE69923439 D1 DE 69923439D1
- Authority
- DE
- Germany
- Prior art keywords
- hiv
- mice
- proteins
- salmonella
- attenuated strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700605 Viruses Species 0.000 title 1
- 241000699670 Mus sp. Species 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 108700010908 HIV-1 proteins Proteins 0.000 abstract 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 abstract 1
- 102100034343 Integrase Human genes 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7394398P | 1998-02-06 | 1998-02-06 | |
| PCT/US1999/002503 WO1999039735A1 (en) | 1998-02-06 | 1999-02-04 | Live vaccine for human immunodeficiency virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69923439D1 true DE69923439D1 (de) | 2005-03-03 |
Family
ID=22116747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69923439T Expired - Fee Related DE69923439D1 (de) | 1998-02-06 | 1999-02-04 | Lebendimpstoff gegen das humane immunodefizient-virus |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1061950B1 (enExample) |
| JP (1) | JP2002502827A (enExample) |
| KR (1) | KR20010040618A (enExample) |
| CN (1) | CN1216640C (enExample) |
| AT (1) | ATE287727T1 (enExample) |
| AU (1) | AU744730B2 (enExample) |
| CA (1) | CA2320489A1 (enExample) |
| DE (1) | DE69923439D1 (enExample) |
| IL (1) | IL137680A0 (enExample) |
| NZ (1) | NZ506093A (enExample) |
| RU (1) | RU2223784C2 (enExample) |
| WO (1) | WO1999039735A1 (enExample) |
| ZA (1) | ZA99912B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2802426B1 (fr) | 1999-12-15 | 2004-04-02 | Neovacs | Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires |
| AU8640501A (en) * | 2000-07-31 | 2002-02-13 | Univ Yale | Innate immune system-directed vaccines |
| KR100447530B1 (ko) * | 2001-08-14 | 2004-09-08 | 한국과학기술원 | ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법 |
| EP1670505B1 (en) | 2003-09-18 | 2012-11-14 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Dna promoters and anthrax vaccines |
| ES2555544T3 (es) | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| CN101195823B (zh) * | 2007-11-20 | 2010-06-02 | 华东理工大学 | 细菌表面展示系统、方法及应用 |
| CN109207417A (zh) * | 2018-09-19 | 2019-01-15 | 湖北省农业科学院畜牧兽医研究所 | 鸡白痢-j亚群禽白血病双重平板凝集抗原及其制备方法 |
| JP2023516420A (ja) * | 2020-03-05 | 2023-04-19 | ユニヴァーシティー オブ メリーランド バルチモア | がんタンパク質抗原を発現するように操作された生チフス菌ベクターおよびその使用方法 |
| WO2025063261A1 (ja) * | 2023-09-22 | 2025-03-27 | 塩野義製薬株式会社 | ウイルス由来タンパク質をコードするポリヌクレオチド |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757013A (en) * | 1983-07-25 | 1988-07-12 | The Research Foundation Of State University Of New York | Cloning vehicles for polypeptide expression in microbial hosts |
| AU9179891A (en) * | 1990-12-19 | 1992-07-22 | Epitope, Inc. | Hiv reverse transcriptase vaccine |
| JP3100005B2 (ja) * | 1992-07-28 | 2000-10-16 | 雪印乳業株式会社 | ヒト免疫不全ウィルス感染・増殖抑制剤 |
| AU3958895A (en) * | 1994-10-18 | 1996-05-06 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
-
1999
- 1999-02-04 JP JP2000530232A patent/JP2002502827A/ja not_active Withdrawn
- 1999-02-04 CN CN998027014A patent/CN1216640C/zh not_active Expired - Fee Related
- 1999-02-04 EP EP99913808A patent/EP1061950B1/en not_active Expired - Lifetime
- 1999-02-04 DE DE69923439T patent/DE69923439D1/de not_active Expired - Fee Related
- 1999-02-04 AT AT99913808T patent/ATE287727T1/de not_active IP Right Cessation
- 1999-02-04 IL IL13768099A patent/IL137680A0/xx unknown
- 1999-02-04 CA CA002320489A patent/CA2320489A1/en not_active Abandoned
- 1999-02-04 WO PCT/US1999/002503 patent/WO1999039735A1/en not_active Ceased
- 1999-02-04 RU RU2000123173/15A patent/RU2223784C2/ru not_active IP Right Cessation
- 1999-02-04 NZ NZ506093A patent/NZ506093A/en unknown
- 1999-02-04 AU AU31801/99A patent/AU744730B2/en not_active Ceased
- 1999-02-04 KR KR1020007008489A patent/KR20010040618A/ko not_active Abandoned
- 1999-02-05 ZA ZA9900912A patent/ZA99912B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE287727T1 (de) | 2005-02-15 |
| RU2223784C2 (ru) | 2004-02-20 |
| AU744730B2 (en) | 2002-02-28 |
| CA2320489A1 (en) | 1999-08-12 |
| IL137680A0 (en) | 2001-10-31 |
| KR20010040618A (ko) | 2001-05-15 |
| AU3180199A (en) | 1999-08-23 |
| NZ506093A (en) | 2003-08-29 |
| EP1061950A1 (en) | 2000-12-27 |
| CN1216640C (zh) | 2005-08-31 |
| WO1999039735A9 (en) | 2000-01-27 |
| EP1061950A4 (en) | 2001-12-05 |
| EP1061950B1 (en) | 2005-01-26 |
| WO1999039735A1 (en) | 1999-08-12 |
| JP2002502827A (ja) | 2002-01-29 |
| CN1290175A (zh) | 2001-04-04 |
| ZA99912B (en) | 2000-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mayr et al. | Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs | |
| Fuchs et al. | First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090) | |
| ATE295895T1 (de) | Genetischer impfstoff gegen den immunschwäche virus | |
| Lambot et al. | Characterization of the immune response of cattle against non-cytopathic and cytopathic biotypes of bovine viral diarrhoea virus | |
| Schmidt et al. | Chikungunya vaccine candidates: current landscape and future prospects | |
| Kawagishi et al. | Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses | |
| FR07C0020I2 (fr) | Proteines de capsides de virus du papillome hpv16 recombinees a auto-assemblage | |
| Masopust | Developing an HIV cytotoxic T‐lymphocyte vaccine: issues of CD8 T‐cell quantity, quality and location | |
| ES2001752A6 (es) | Procedimiento para producir una vacuna de herpesvirus, y para produciruna vacuna multivalente. | |
| Cromwell et al. | Induction of mucosal homing virus-specific CD8+ T lymphocytes by attenuated simian immunodeficiency virus | |
| Brewoo et al. | Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice | |
| ATE287727T1 (de) | Lebendimpstoff gegen das humane immunodefizient- virus | |
| Martins et al. | What is the predictive value of animal models for vaccine efficacy in humans? Rigorous simian immunodeficiency virus vaccine trials can be instructive | |
| Yuan | Vaccine Efficacy Evaluation: The Gnotobiotic Pig Model | |
| Medina-Magües et al. | Immunogenicity of poxvirus-based vaccines against Nipah virus | |
| Flynn et al. | Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination | |
| Wang et al. | Insertion of type O-conserved neutralizing epitope into the foot-and-mouth disease virus type Asia1 VP1 GH loop: effect on viral replication and neutralization phenotype | |
| Grant et al. | The B-cell response to foot-and-mouth-disease virus in cattle following vaccination and live-virus challenge | |
| McChesney et al. | New directions for HIV vaccine development from animal models | |
| Garcia et al. | New approaches to chikungunya virus vaccine development | |
| Ada | Twenty years into the saga of MHC‐restriction | |
| Haberthur et al. | Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaques | |
| Shacklett et al. | Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251 | |
| Grund et al. | Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies | |
| Korioth-Schmitz et al. | Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |